ClearPoint Neuro reported third quarter 2026 revenue of $12.1 million, a 36% year-over-year increase, narrowly missing analyst estimates of $12.3 million. The company demonstrated significant growth in its clinical product lines, though it narrowed its full-year 2026 revenue guidance to the lower half of its previous range. Net loss for the quarter was $0.24 per share, performing better than the anticipated $0.32 loss.
Key Highlights
- Neurosurgery navigation and therapy revenue surged 59% to $5.4 million, driven by the successful integration of the IRRAflow portfolio.
- Biologics and drug delivery revenue grew 11% to $4.9 million, supported by increased service demand at ClearPoint Advanced Laboratories.
- A significant regulatory milestone was achieved with a partner's first formal BLA submission for a Huntington's Disease treatment.
- Capital equipment and software revenue reached a record $1.7 million, representing 68% growth in the quarter.